CytoMed Therapeutics (GDTC) Invested Capital (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Invested Capital for 5 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 21.33% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 21.33% year-over-year, with the annual reading at $5.6 million for FY2025, 19.27% down from the prior year.
  • Invested Capital hit $5.6 million in Q4 2025 for CytoMed Therapeutics, down from $7.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $8.7 million in Q4 2023 to a low of $785343.4 in Q4 2022.
  • Historically, Invested Capital has averaged $4.8 million across 5 years, with a median of $5.6 million in 2025.
  • Biggest five-year swings in Invested Capital: tumbled 59.24% in 2022 and later surged 1002.15% in 2023.
  • Year by year, Invested Capital stood at $1.9 million in 2021, then crashed by 59.24% to $785343.4 in 2022, then soared by 1002.15% to $8.7 million in 2023, then fell by 17.7% to $7.1 million in 2024, then decreased by 21.33% to $5.6 million in 2025.
  • Business Quant data shows Invested Capital for GDTC at $5.6 million in Q4 2025, $7.1 million in Q4 2024, and $8.7 million in Q4 2023.